These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7962225)

  • 1. Bioequivalence of two oral dosage forms prepared from different polymorphic modifications of tenoxicam.
    Salem MS; Alkaysi HN; Gharaibeh AM; Gharaibeh NM; Badwan AA
    J Clin Pharm Ther; 1994 Jun; 19(3):203-7. PubMed ID: 7962225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers.
    Palma-Aguirre JA; Lopez-Gamboa M; Cariño L; Burke-Fraga V; González-de la Parra M
    Clin Ther; 2010 Feb; 32(2):357-64. PubMed ID: 20206793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Br J Clin Pharmacol; 1994 Jan; 37(1):79-81. PubMed ID: 8148224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal delivery of tenoxicam in rat.
    Raghavan CV; Abimon VD
    Int J Pharm; 2001 Jun; 221(1-2):227-9. PubMed ID: 11397584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
    Kim T; Kang E; Chun I; Gwak H
    J Pharm Pharmacol; 2008 Jan; 60(1):135-8. PubMed ID: 18088513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of intramuscularly administered tenoxicam.
    Stebler T; Guentert TW
    Biopharm Drug Dispos; 1993 Aug; 14(6):483-90. PubMed ID: 8218966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of oral dosage forms of tenoxicam.
    Guentert TW; Stebler T; Banken L; Defoin R; Schmitt M
    Arzneimittelforschung; 1994 Sep; 44(9):1051-4. PubMed ID: 7986242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma tenoxicam concentrations after single and multiple oral doses.
    Crevoisier C; Heizmann P; Forgo I; Dubach UC
    Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenoxicam: acute dose-dependent disposition studies in rats.
    Lopez-Bustamante LG; Troconiz JI; Fos D
    J Pharm Sci; 1993 Aug; 82(8):851-3. PubMed ID: 8377127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced bioavailability of piroxicam via salt formation with ethanolamines.
    Gwak HS; Choi JS; Choi HK
    Int J Pharm; 2005 Jun; 297(1-2):156-61. PubMed ID: 15907602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC determination of piroxicam in human plasma.
    Dadashzadeh S; Vali AM; Rezagholi N
    J Pharm Biomed Anal; 2002 Jun; 28(6):1201-4. PubMed ID: 12049984
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of tenoxicam at different dosage regimes.
    Scaglione F; Demartini G; Dugnani S; Fraschini F; Triscari FA
    Farmaco; 1993 Sep; 48(9):1321-5. PubMed ID: 8259988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
    Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E
    Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam.
    Motawea A; Borg T; Tarshoby M; Abd El-Gawad AE
    Pharm Dev Technol; 2017 May; 22(3):445-456. PubMed ID: 27583581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
    Helmy SA; El-Bedaiwy HM
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):466-71. PubMed ID: 27129120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lornoxicam Immediate-Release Tablets: Formulation and Bioequivalence Study in Healthy Mediterranean Volunteers Using a Validated LC-MS/MS Method.
    Zaid AN; Mousa A; Jaradat N; Bustami R
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):564-569. PubMed ID: 28176487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals.
    Troconiz JI; Lopez-Bustamante LG; Fos D
    Arzneimittelforschung; 1993 Jun; 43(6):679-81. PubMed ID: 8352822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
    Moutasim MY; ElMeshad AN; El-Nabarawi MA
    Drug Deliv Transl Res; 2017 Jun; 7(3):450-459. PubMed ID: 28283842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.